Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria  

作　　者：Nathália N Chamma-Siqueira 

机构地区：[1]不详

出　　处：《四川生理科学杂志》2022年第2期347-347,共1页Sichuan Journal of Physiological Sciences

摘　　要：Background:In most of the Americas,the recommended treatment to prevent relapse of Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body weight,despite evidence of only moderate efficacy.Methods:In this trial conducted in Brazil,we evaluated three primaquine regimens to prevent relapse of P.vivax malaria in children at least 5 years of age and in adults with microscopy-confirmed P.vivax monoinfection.All the patients received directly observed chloroquine for 3 days(total dose,25 mg per kilogram).Group 1 received a total primaquine dose of 3.5 mg per kilogram(0.5 mg per kilogram per day)over 7 days with unobserved administration;group 2 received the same regimen as group 1 but with observed administration;and group 3 received a total primaquine dose of 7.0 mg per kilogram over 14 days(also 0.5 mg per kilogram per day)with observed administration.We monitored the patients for 168 days.

关 键 词：VIVAX MALARIA REGIMEN 

分 类 号：R53[医药卫生—内科学]